Cohort | Subject number | Sex/age | WHO diagnosis | Donor | GVHD gradea | Cycle (mg/m2/day for 5Â days) | ||||
---|---|---|---|---|---|---|---|---|---|---|
Acute | Chronic | 1 | 2 | 3 | 4 | |||||
1 | 1 | F/19 | RAEB-2 | MSD | 0 | 0 | 5b,c | 1.5 | 1.5 | 1.5 |
2 | M/36 | AML | MSD | 0 | 0 | 5b | 6 | 5.5 | 6 | |
3 | M/60 | RAEB-2 | MUD | 1 | 0 | 5 | – | – | – | |
4 | M/48 | AML | MSD | 0 | 0 | 5b,c | 1.5 | 2.5 | 3 | |
2 | 5 | M/64 | RAEB-2 | PMUD | 1 | 0 | 4b | 4 | 5.5 | 7 |
6 | F/43 | RAEB-2 | MSD | 0 | 0 | 4b | 7 | 8 | 12 | |
7 | M/64 | AML | MSD | 0 | 0 | 4b | 6 | 5.5 | 5.5 | |
3 | 8 | F/51 | RAEB-2 | MUD | 1 | 0 | 5b | 7.5b,c | 7.5c | 7 |
9 | F/59 | RAEB-1 | MUD | 2 | 0 | 5b,c | 3.5 | 4 | 4.5 | |
10 | F/36 | RAEB-2 | MUD | 1 | 0 | 5b | 6b | 8.5 | 9 | |
4 | 11 | M/64 | RAEB-2 | MSD | 2 | 0 | 5.5b | 2b | – | – |
12 | M/60 | RAEB-2 | MSD | 0 | Mild | 5.5b,c | 4.5b | 7 | 8 | |
13 | M/41 | RAEB-2 | MSD | 0 | 0 | 5.5b,c | 3 | 5 | 8 | |
5 | 14 | M/49 | AML | MUD | 2 | 0 | 5b | 1.5 | 2.5 | 3 |
15 | F/50 | AML | MSD | 2 | 0 | 5b,c | 4 | 6 | 9 | |
16 | F/49 | RAEB-2 | MSD | 2 | 0 | 5b | 7.5 | 8 | 11c |